238 related articles for article (PubMed ID: 10363910)
1. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
[TBL] [Abstract][Full Text] [Related]
2. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
3. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
Poduslo JF; Curran GL; Sanyal B; Selkoe DJ
Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
[TBL] [Abstract][Full Text] [Related]
4. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Ramirez-Alvarado M; Poduslo JF
J Pharmacol Exp Ther; 2006 Jul; 318(1):17-25. PubMed ID: 16565169
[TBL] [Abstract][Full Text] [Related]
5. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.
Poduslo JF; Curran GL; Haggard JJ; Biere AL; Selkoe DJ
Neurobiol Dis; 1997; 4(1):27-34. PubMed ID: 9258909
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation.
Soto C; Kindy MS; Baumann M; Frangione B
Biochem Biophys Res Commun; 1996 Sep; 226(3):672-80. PubMed ID: 8831674
[TBL] [Abstract][Full Text] [Related]
7. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat.
Reinholz MM; Haggard JJ; Curran GL; Poduslo JF
Exp Neurol; 1999 Sep; 159(1):191-203. PubMed ID: 10486187
[TBL] [Abstract][Full Text] [Related]
9. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits.
Chacón MA; Barría MI; Soto C; Inestrosa NC
Mol Psychiatry; 2004 Oct; 9(10):953-61. PubMed ID: 15098004
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide.
Wiesehan K; Stöhr J; Nagel-Steger L; van Groen T; Riesner D; Willbold D
Protein Eng Des Sel; 2008 Apr; 21(4):241-6. PubMed ID: 18252750
[TBL] [Abstract][Full Text] [Related]
11. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.
Nakagami Y; Nishimura S; Murasugi T; Kaneko I; Meguro M; Marumoto S; Kogen H; Koyama K; Oda T
Br J Pharmacol; 2002 Nov; 137(5):676-82. PubMed ID: 12381681
[TBL] [Abstract][Full Text] [Related]
12. Targeting alzheimer amyloid plaques in vivo.
Wengenack TM; Curran GL; Poduslo JF
Nat Biotechnol; 2000 Aug; 18(8):868-72. PubMed ID: 10932157
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
14. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
17. Design and biological activity of beta-sheet breaker peptide conjugates.
Rocha S; Cardoso I; Börner H; Pereira MC; Saraiva MJ; Coelho M
Biochem Biophys Res Commun; 2009 Mar; 380(2):397-401. PubMed ID: 19250644
[TBL] [Abstract][Full Text] [Related]
18. Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats.
Liu Y; Liu H; Yang J; Liu X; Lu S; Wen T; Xie L; Wang G
Neuroscience; 2008 May; 153(3):796-802. PubMed ID: 18424002
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE; Johanson CE
J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid.
Schuster D; Rajendran A; Hui SW; Nicotera T; Srikrishnan T; Kruzel ML
Neuropeptides; 2005 Aug; 39(4):419-26. PubMed ID: 15890402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
